<DOC>
	<DOCNO>NCT02644668</DOCNO>
	<brief_summary>The primary objective study demonstrate pharmacodynamic effect CK-2127107 measure skeletal muscle function fatigability patient Spinal Muscular Atrophy Types II-IV .</brief_summary>
	<brief_title>A Study CK-2127107 Patients With Spinal Muscular Atrophy</brief_title>
	<detailed_description>This first study conduct patient design assess effect 8 week dose CK-2127107 measure muscle function ambulatory non-ambulatory patient SMA . The plasma concentration CK-2127107 measure select time point course dose plasma concentration obtain study may use conduct exposure-response analysis .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy , Spinal</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<criteria>Able comprehend willing sign Informed Consent Form ( ICF ) patient 18 year age old . For patient le 18 year age , parent ( ) /legal guardian ( ) patient must provide write informed consent prior participation study inform assent obtain minor least 12 year age require regulation . Males females genetically confirm diagnosis SMA Type II , III IV least 12 year age Ambulatory patient , achieve stand position independently , must able complete least one lap 6minute walk test ( least 50 meter ) within 5 minute without assistance . Nonambulatory patient ( defined individual unable stay stand position independently unable take step personal assistance assistive device ; effectively require wheelchair mobility need ) must able tolerate upright sit position , support , continuously 3 hour Hammersmith ( HFMSE ) score ≥ 10 ≤ 54 Contracture elbow flexion knee flexion ≤ 90 degree Prestudy clinical laboratory finding within normal range , outside normal range , deem clinically significant Investigator Able swallow oral suspension opinion Investigator , expect continue able duration trial . Administration via feed tube allow . Forced vital capacity ( FVC ) &gt; 20 % predict threshold great 3 month Male patient reach puberty must agree either follow Screening 10 week last dose investigational product unless vasectomy confirm sperm count zero : Abstain sexual intercourse , OR If heterosexual intercourse , must use condom female partner childbearing potential must use highly effective contraception method* Female patient first period consider childbearing potential unless anatomically physiologically incapable become pregnant . If childbearing potential , female patient must : Have negative urine/serum pregnancy test Screening AND Abstain heterosexual intercourse Screening 10 week last dose investigational product OR If heterosexual intercourse , must use highly effective contraception method* require male partner use condom Screening 10 week last dose investigational product *Highly effective contraception method include : Established use oral , injected implant hormonal method contraception Placement intrauterine device ( IUD ) intrauterine system ( IUS ) Male patient must agree refrain sperm donation Screening 10 week final study drug administration History significant hypersensitivity , intolerance , allergy drug compound , food , substance , unless approve Investigator Hospitalization within 2 month Screening History stomach intestinal surgery resection would potentially alter absorption and/or excretion orally administer drug ( appendectomy , hernia repair , and/or cholecystectomy allow ) A clinically significant illness within 4 week Screening History alcoholism drug addiction within 2 year prior Screening History smoke 10 cigarette ( equivalent amount tobacco ) per day within 3 month prior Screening Patient use strong CYP3A4 inhibitor within 7 day prior first dose study drug strong CYP3A4 inducer within 14 day prior first dose study drug Any medical condition would interfere performance test include ( limited ) significant joint pain arthritis limit mobility , chronic neuromuscular pain sufficient require ongoing analgesic medication Participation two people time live household Participation investigational study drug trial receipt investigational study drug occur within 30 day five halflives investigational study drug , whichever great , prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>